Impact of low molecular weight heparin administration on the clinical course of the COVID-19 disease

Burcu YORMAZ1,*, Dilek ERGÜN1, Baykal TÜLEK1, Recai ERGÜN1, Uğur ARSLAN2, Fikret KANAT1

1Department of Pulmonology, Faculty of Medicine, Selçuk University, Konya, Turkey
2Department of Microbiology, Faculty of Medicine, Selçuk University, Konya, Turkey

Received: 16.06.2020 ● Accepted/Published Online: 20.08.2020 ● Final Version: 26.02.2021

Background: Lymphopenia is the most important criterion of mortality and discharging feature for patients infected with coronavirus disease 2019 (COVID-19). This study aimed to investigate the clinical impact of a low molecular weight heparin (LMWH) treatment on the clinical course of COVID-19.

Materials and methods: Patients’ clinical symptoms, radiologic outcomes, hematologic, biochemical, D-dimer, and C-reactive protein (CRP) results were obtained from their medical records. Participants were separated into 2 groups: one was treated with LMWH and the other was not. Improvement in the patients was compared before and after treatment.

Results: Ninety-six patients who were diagnosed with COVID-19 between April and May 2020 were retrospectively analyzed. The multivariable analysis showed that the count of lymphocytes, D-dimer, and CRP levels were significantly improved in the LMWH group, as compared to the control group (OR, (95% CI) 0.628 (0.248–0.965), P < 0.001; OR, (95% CI) 0.356 (0.089–0.674), P < 0.001, respectively). The area under the receiver operating characteristic (ROC) curve analysis was AUC: 0.679 ± 0.055, 0.615 ± 0.058, and 0.633 ± 0.057, respectively; the β-value was found to be –1.032, –0.026, and –0.465, respectively.

Conclusion: The LMWH treatment group demonstrated better laboratory findings, including recovery in the lymphocyte count, CRP, and D-dimer results.

Key words: Coronavirus disease-19, heparin, antiinflammatory, lymphocyte

1. Introduction
The COVID-19 disease is an illness caused by a respiratory and systemic zoonotic coronavirus. It was first recognized in Wuhan, China, and it has continued to spread rapidly since then. It has become a global calamity, and the World Health Organization (WHO) declared the disease a pandemic on March 11, 2020. Over 2 million people worldwide have been infected so far, and mortality continues to rise. However, no effective medical cure is available, and patients are treated according to their symptoms and findings [1,2].

Helpful strategies for improvement of the illness may be devised if the pathophysiology is understood. Lymphopenia and cytokine storms are the typical pathological changes detected in patients with coronavirus infections; they relate to COVID-19 severity. The cytokine storm is a key mechanism underlying disease exacerbation and mortality in COVID-19 patients [3–5]. Some studies have indicated that low molecular weight heparin (LMWH) has some properties other than its anticoagulant effects, such as its antiinflammatory action, which ensures improvement in lymphopenia [6]. However, although the antiinflammatory effects of LMWH in COVID-19 remain unclear, it is thought that the antiinflammatory efficacy contributes to the regression of COVID-19 [7]. The aim of this study is to assess the clinical impact of LMWH treatment on the clinical course of COVID-19.

2. Material and methods
In this study, 96 participants who were admitted to the Selcuk University Hospital, Department of Pulmonology between March and April 2020 were analyzed retrospectively. The patients’ clinical outcomes were investigated by studying their electronic medical records. COVID-19 was diagnosed according to WHO guidelines. This study was approved by the Ministry of Health Committee (approval number: 2020/37) and conducted in accordance with the principles of the Declaration of Helsinki [2].

* Correspondence: burcystals@gmail.com

This work is licensed under a Creative Commons Attribution 4.0 International License.
Blood samples were gathered during the length of the stay in the hospital: D-dimer, prothrombin time (PT), international normalized ratio (INR), and fibrinogen (FIB) measurements were investigated by utilizing a coagulation analyzer device.

Participants were separated into 2 groups according to D-dimer (D-dimer > 750 ng/mL) and PT (<12 s) outcomes due to mortality, raised accordingly with D-dimer, PT levels, and given appropriate thromboprophylaxis with LMWH (a thromboprophylactic dose of 4000 UI/day for 7 days). No anticoagulant drugs other than heparin were utilized for 7 days or longer in the research patients. All the participants received appropriate treatment after admission to the hospital [8–10].

2.1. Inclusion criteria
The inclusion criteria included: 1) satisfying the conditions of the diagnostic standards of COVID-19 pneumonia outlined by the Health Commission of Turkey; 2) identified as tightness of breath, respiration rate (RR) ≥ 30/min, detected typical lesions in CT images of viral pneumonia; 3) age ≥18 years; 4) no history of any pulmonary disease; and 5) no immunosuppressive or corticosteroid agent administered during the therapy period.

2.2. Exclusion criteria
The exclusion criteria included: 1) participants with severe chronic diseases; 2) patients who had liver, kidney, or cardiac disease; 3) patients who had taken LMWH therapy in the last 3 months; 4) patients with a history of mental disorders; 5) women who were pregnant or breastfeeding; 6) patients who had followed-up in the intensive care unit (ICU); and 7) patients with any sensitivity to LMWH.

2.3. Chest CT severity score assessment
The computer tomography severity score (CT-SS) was utilized to evaluate patients with COVID-19. The CT-SS is an adapted version of the scoring system, describing ground glass, interstitial opacity, and air trapping for severe acute respiratory syndrome (SARS). This scoring system assesses pulmonary lesions as a guide for detecting the disease [11]. The lungs were separated into 20 zones, according to human anatomy. The detected pulmonary opacities in all zones were assessed by thin section thorax CT (TST-CT), using system linked scores of 0, 1, and 2, according to opacification, including 0%, < 50%, or ≥ 50% of every zone. The total scores, which ranged between 0 and 40 points, were obtained from each zone collected. Two experienced thorax radiologists, who were blinded to the identity of the participants, evaluated all the CT screenings. Chest CT scans were performed with a 256-detector CT scanner (Siemens, Germany). All the participants were lying in the supine position, and the scan was performed during the breath hold situation [11].

2.4. Data collection
The demographic characteristics (age, sex, and BMI), signs and symptoms, clinical outcomes, initial knowledge, complete blood count (CBC), D-dimer, FIB, coagulation profile, inflammatory markers, biochemical markers (such as liver function, CRP, and electrolytes), and the TST-CT of patients infected with COVID-19 were assessed retrospectively (Tables 1–3). Two researchers assessed the collected data forms independently.

2.5. Statistical analysis
The R 3.6.0 (www.r-project.com) was used to perform all the statistical analyses. The Anderson–Darling test and Q-Q plots were used to check the normality of the variables. The homogeneity of the variances by group was examined using the Levene's test. Data was described as mean ± standard deviation (range), median (interquartile range), and numbers (%) for the general characteristics of the patients with COVID-19. Welch’s t-test, the Mann–Whitney U test, the χ² test, with the Yates continuity correction, and Fisher's exact test were used, as appropriate, to compare the general characteristics between the patient groups. Considering the possible extreme outliers under pandemic conditions, the values for the laboratory findings were presented as trimmed mean (±SEM: standard error of mean), which was calculated with a 10% trim proportion and a robust estimator against the outliers. Yuen's test (robust independent-samples t-test) and the robust paired-samples t-test were used to compare these findings. The comparisons were applied considering 4 situations: the LMWH and the control groups before treatment, the LMWH and the control groups on the 7th day of treatment, and the LMWH group before treatment and on the 7th day of treatment (Figures 1 and 2). Finally, calculated changes were compared by taking the difference of the 7th day and before the treatment in both groups; P < 0.001 was considered statistically significant. Univariate logistic regression analysis was utilized to view risk factors. A multivariate logistic regression analysis was performed to evaluate the efficacy of the variant risk factors on the participant's discharge and scoring system; the odds ratio (OR) and 95% confidence interval (CI) were calculated (Tables 4,5). The forecasting value of the lymphocyte count, D-dimer, and CRP, as assessed by the ROC curve and the cut-off value, which may predict the discharge, were identified afterward.

2.6. ROC curve analysis
The recovery performances of the laboratory parameters were evaluated by ROC analysis on the 7th day, as shown in Figure 3. The cut-off point for these parameters was determined according to the Youden index value. Risk factors included the lymphocyte counts, the level of CRP, and the D-dimer. The contributions of the risk factors were
determined based on the $\beta$ value presented in Table 5. The area under the ROC curve for dividing the participants’ LMWH, as compared to the control group, was applied for the threshold sensitivity, specificity, and accuracy. It was OR; 0.356 (standard error, 0.001; 95% CI, 0.089–0.674, $\beta$; –1.032) for lymphocyte, OR; 0.974 (standard error, 0.001; 95% CI, 0.476–1.594, $\beta$; –0.026) for D-dimer, and OR; 0.628 (standard error, 0.001; 95% CI, 0.248–0.965, $\beta$; –0.465) for CRP. The optimal threshold for identifying patients was 1.39, with 66.7% sensitivity and 64.6% specificity; 414, with 39.6% sensitivity and 85.4% specificity; and 14.3, with 58.3% sensitivity and 64.6% specificity, respectively.

3. Results

3.1. General characteristics of the patients with COVID-19

The LMWH group consisted of 15 males and 33 females aged between 40 and 68 years (average age: 53.3 years), as shown in Table 1. The control group consisted of 18 males and 30 females aged between 44 and 66 years (average age: 55.4 years). There was no substantial difference detected between the groups.

| Characteristics          | LMWH Group (n = 48) | Control Group (n = 48) | P-value |
|--------------------------|---------------------|------------------------|---------|
| Age (years)              | 53.3 ± 15.6         | 55.4 ± 11.6            | 0.469   |
| Sex                      | 0.667               |                        |         |
| Female                   | 15 (31.3)           | 18 (37.5)              |         |
| Male                     | 33 (68.8)           | 30 (62.5)              |         |
| Comorbidity              | 29 (60.4)           | 28 (58.3)              | 0.718   |
| Hypertension             | 17 (35.4)           | 18 (37.5)              | 0.617   |
| Diabetes mellitus        | 14 (29.2)           | 10 (20.8)              | 0.123   |
| Coronary artery disease  | 7 (12.2)            | 5 (8.7)                | 0.831   |
| Gastrointestinal disease | 1 (2.1)             | 2 (4.2)                | 0.512   |
| Other disease            | 6 (12.5)            | 3 (6.3)                | 0.486   |

Values were presented as mean ± standard deviation (min–max), median (min–max) or numbers (n) and percentages (%). P-values were calculated by Welch’s t-test, Mann–Whitney U test, $\chi^2$ test with Yates continuity correction or Fisher’s exact test, as appropriate.

As shown in Table 2, the number of days it takes to convert the virus to a negative outcome (time from the beginning of the stay in the hospital until virus shedding) was 5.2 days (IQR 3.4–6.3) in the LMWH group and 7.6 days (IQR 6.5–9.7) in the control group (P < 0.001). A significant difference was detected between the groups. Also, the length of the stay in the hospital was 7.2 days (IQR 6.4–8.3) in the heparin group and 9.6 days (IQR 8.5–10.7) in the control group (P < 0.001). A significant difference was detected between the groups. All of the participants demonstrated improvement after the treatment.

3.3. Effect of LMWH on the blood routine in patients with COVID-19

A significant difference was detected in the lymphocyte count between the groups before and after treatment, as shown in Table 2. The after-treatment lymphocyte count of the LMWH treatment group participants was elevated, and the detected difference was significant. In addition, the changes in the lymphocyte counts in the LMWH group...
group before and after therapy were significantly different according to the control group.

After treatment, the platelet results and levels were significantly elevated in the LMWH group, compared to the control group. However, there was no significant difference detected between the groups in the monocyte, neutrophil percent, white blood cell (WBC), or hemoglobin levels.

3.4. Effect of LMWH on the coagulation function in patients with COVID-19

The levels of the D-dimer and fibrin products prior to the application of LMWH in both groups were nonsignificant; however, these outcomes were significantly decreased after the LMWH treatment in the LMWH group, compared to the control group, as shown in Table 3. The patients’ levels of D-dimer and FIB were significantly decreased in the LMWH group prior to and after treatment. The outcomes show that the application of LMWH improves the hypercoagulable state in COVID-19 patients. However, there was no significant difference detected in PT and INR levels among the groups.

3.5. Effect of LMWH on the CRP in patients with COVID-19

There were significant differences detected in the CRP levels between the groups both prior to and after LMWH treatment, as shown in Table 3. Although the CRP levels were initially similar between the groups, these outcomes were significantly decreased in the LMWH group.

| Table 2. Signs, symptoms, and clinical outcomes. |
|-----------------------------------------------|
|                                                                                             |
|                                                                                             |
| **Signs**                                    | **LMWH Group (n = 48)** | **Control (n = 48)** | **P-value** |
| Fever (temperature ≥37°C)                    | 38 (79.1%)              | 36 (75.0%)           | 0.808       |
| Dry cough                                    | 33 (68.8%)              | 30 (62.5%)           | 0.667       |
| Shortness of breath                          | 24 (50.0%)              | 28 (58.3%)           | 0.413       |
| Sputum                                       | 13 (27.1%)              | 14 (29.2%)           | 0.825       |
| Myalgia                                      | 10 (20.8%)              | 16 (33.3%)           | 0.251       |
| Throat ache                                   | 8 (16.7%)               | 6 (12.5%)            | 0.772       |
| Nausea or vomiting                           | 1 (2.1%)                | 6 (12.5%)            | 0.135       |
| Diarrhea                                     | 3 (6.9%)                | 4 (8.3%)             | 0.683       |
| Headache                                     | 4 (8.3%)                | 2 (4.2%)             | 0.277       |
| Time from initial symptoms to admission to hospital (days) | 2.2(1.1–3.4)           | 2.4(1.6–3.2)         | 0.816       |
| Time from hospitalization to viral shedding of disease (days) | 5.2 (3.4–6.3)           | 7.6 (6.5–9.7)        | <0.001      |
| Length of stay in hospital                   | 7.2 (6.4–8.3)           | 9.6 (8.5–10.7)       | <0.001      |
| Antibiotic therapy                           | 48                      | 48                   | 0.997       |
| Azitromycin                                  | 38 (79.1%)              | 39 (81.2%)           |             |
| Moxifloxacin                                 | 42 (87.5%)              | 41 (85.4%)           |             |
| Antiviral therapy                            |                         |                      | 0.994       |
| Favipiravir                                   | 32 (66.6%)              | 33 (68.7%)           |             |
| Oseltamivir                                   | 43 (89.5%)              | 42 (87.5%)           |             |
| Response to treatment                        |                         |                      |             |
| Improved                                     | 48 (100%)               | 30 (62.5%)           | 0.212       |
| Steady                                       | 0                       | 18 (37.5%)           |             |
| Disruptive                                   | 0                       | 0                    |             |
| CT-SS                                        |                         |                      |             |
| Score of left lung                           | 5.0 (4.0–6.0)           | 6.0 (5.0–8.0)        | <0.001      |
| Score of right lung                          | 5.0 (3.75–6.0)          | 7.5 (6.0–95)         | <0.001      |
| Total score                                  | 11.0 (7.0–12.5)         | 13.5 (12.5–16.0)     | <0.001      |

CT-SS: CT severity score
3.6. Effect of LMWH on the cardiac markers in patients with COVID-19

As shown in Table 3, there were no significant differences detected in the creatine kinase isoenzyme B (CK-MB) levels between the groups prior to and after LMWH treatment, and the results of both groups were decreased, as compared to prior to treatment. Similarly, there were no significant differences detected in the troponin-I levels between the 2 groups.

3.7. Effect of LMWH on the CT-SS in patients with COVID-19

As shown in Table 3, there were significant differences detected in the CT-SS between the groups prior to and after LMWH treatment. Although the CT-SS was initially similar between the groups, these outcomes decreased significantly after LMWH treatment in the LMWH group, as compared to the control group.

Table 3. Laboratory findings and scores during the treatment period.

|                         | Initial values | 7th day of the treatment | LMWH (n = 48) | Control (n = 48) | p<sup>a</sup> | p<sup>b</sup> | p<sup>c</sup> |
|-------------------------|----------------|--------------------------|--------------|-----------------|-------------|-------------|-------------|
| WBC (k/uL)              | 9.26 ± 0.76    | 9.51 ± 0.80              | 6.40 ± 0.41  | 6.91 ± 0.37     | 0.497       | 0.365       | 0.435       |
| Neutrophil (k/uL)       | 5.43 ± 0.54    | 4.88 ± 0.43              | 4.95 ± 0.45  | 4.84 ± 0.32     | 0.402       | 0.828       | 0.408       |
| Monocyte (k/uL)         | 0.55 ± 0.05    | 0.52 ± 0.04              | 0.58 ± 0.03  | 0.65 ± 0.05     | 0.609       | 0.260       | 0.523       |
| Monocyte percent (%)    | 7.39 ± 0.49    | 7.93 ± 0.64              | 7.87 ± 0.53  | 8.99 ± 0.67     | 0.491       | 0.175       | 0.318       |
| Lymphocyte (k/uL)       | 0.77 ± 0.03    | 0.82 ± 0.02              | 1.39 ± 0.40  | 1.02 ± 0.03     | 0.094       | <0.001      | <0.001      |
| Lymphocytes percent (%) | 12.41 ± 1.06   | 13.66 ± 0.84             | 22.18 ± 2.02 | 19.86 ± 1.46    | 0.205       | <0.001      | <0.001      |
| HB (g/dL)               | 12.80 ± 0.35   | 13.29 ± 0.27             | 12.31 ± 0.31 | 12.96 ± 0.25    | 0.242       | 0.089       | 0.001       |
| PLT (k/uL)              | 181.72 ± 11.83 | 189.05 ± 9.58            | 220.60 ± 11.17 | 229.15 ± 13.28 | 0.618       | 0.610       | <0.001      |
| ALT (U/L)               | 44.12 ± 5.26   | 43.63 ± 6.23             | 35.16 ± 3.64 | 36.17 ± 4.28    | 0.879       | 0.826       | 0.853       |
| AST (U/L)               | 42.27 ± 3.45   | 43.72 ± 4.48             | 37.83 ± 4.95 | 35.82 ± 3.59    | 0.911       | 0.868       | 0.889       |
| TB (mmol/L)             | 1.04 ± 0.13    | 1.06 ± 0.24              | 0.98 ± 0.26  | 1.00 ± 0.14     | 0.752       | 0.842       | 0.892       |
| Na                      | 138.25 ± 3.45  | 141.40 ± 2.48            | 142.26 ± 3.25 | 144.52 ± 4.28  | 0.764       | 0.815       | 0.795       |
| K                       | 4.32 ± 1.13    | 4.46 ± 1.48              | 4.53 ± 1.26  | 4.61 ± 2.01     | 0.827       | 0.874       | 0.855       |
| Cre                     | 1.10 ± 0.25    | 1.16 ± 0.44              | 0.98 ± 0.55  | 1.01 ± 0.62     | 0.745       | 0.825       | 0.794       |
| CK-MB (ng/mL)           | 1.22 ± 0.15    | 1.28 ± 0.11              | 1.25 ± 0.15  | 1.33 ± 0.12     | 0.738       | 0.663       | 0.827       |
| Troponin-I (ng/L)       | 9.46 ± 2.56    | 5.71 ± 0.79              | 9.06 ± 2.33  | 8.48 ± 0.99     | 0.152       | 0.089       | 0.750       |
| PT (sn)                 | 11.16 ± 0.15   | 13.36 ± 0.31             | 15.05 ± 0.13 | 11.78 ± 0.38    | 0.256       | <0.001      | <0.001      |
| INR (INR)               | 1.03 ± 0.02    | 1.23 ± 0.03              | 1.43 ± 0.02  | 1.11 ± 0.04     | 0.540       | 0.069       | 0.229       |
| D-DIMER (ng/mL) < 414   | 815.02 ± 112.24 | 650 ± 59.68              | 414.10 ± 45.73 | 635.63 ± 39.96 | 0.182       | <0.001      | <0.001      |
| CRP (mg/L)              | 43.66 ± 9.93   | 41.76 ± 7.20             | 14.32 ± 4.46 | 36.62 ± 3.09    | 0.134       | <0.001      | <0.001      |
| FIB                     | 588.24 ± 10.25 | 595.35 ± 12.36           | 326.35 ± 12.25 | 550.37 ± 15.38 | 0.627       | <0.001      | <0.001      |
| CT-SS                   | 15.0 (12.0–16.0) | 13.3 (13.5–16.5)      | 11.0 (7.0–12.5) | 13.5 (12.5–16.0) | 0.983       | <0.001      | <0.001      |

Values were presented as trimmed mean ± SEM (trimmed mean was calculated with 10% trim proportion); (SEM: standard error of mean).

P-values were calculated with Yuen’s test (robust independent samples t-test) and robust paired samples t-test.

P<sup>a</sup> shows the comparison between LMWH and control groups before the treatment.

P<sup>b</sup> shows the comparison between LMWH and control groups on the 7th day of the treatment.

P<sup>c</sup> shows the comparison between before and on the 7th day of treatment in the LMWH group.

Abbreviations: WBC: white blood cell; HB: hemoglobin; PLT: platelet; CK-MB: creatine kinase–myocardial band isoenzyme; PT: prothrombin time; INR: international normalized ratio; CRP: C-reactive protein; FIB: fibrinogen; ALT: alanineaminotransferase; AST: aspartateaminotransferase; TB: total bilirubine; K: potassium; Na: sodium, Cre: creatinine.
4. Discussion

Cytokine storms are related to corruption in infectious illnesses, such as SARS and Middle East respiratory syndrome coronavirus (MERS); they are also an important cause of exacerbation in patients. Studies have revealed that heparin has some specifications other than anticoagulant properties. It performs antiinflammatory actions by decreasing the extrication and biological efficacy of IL-6. However, the antiinflammatory effects of heparin in the COVID-19 disease are not fully known. The main finding of this study is to evaluate the impact of LMWH administration on the clinical course of the COVID-19 disease [12].

Although some studies have investigated the nonanticoagulant efficacy of LMWH, the real impact mechanism of LMWH remains unknown. This study investigated the antiinflammatory effect of the LMWH molecule and its contribution to improvement in the COVID-19 disease. LMWH is a heterogeneous molecule, and it has some features other than its anticoagulant effects. One of the effects of LMWH application is that it leads to a decline in inflammation. Heparin inhibits inflammation by its anticoagulant efficacy; these properties are closely intertwined. Some studies have investigated its antiinflammatory effect. In an experimental model, Downing et al. found that LMWH reduced inflammation and performed this efficacy without any anticoagulant effects. Ahmed et al. also showed that inhaled heparin led to an improvement in pulmonary functions and airway hypersensitivity in asthmatic patients [13,14].

Although the initial results were similar in the assay of distinctions of the lymphocyte counts, after the therapy period, the lymphocyte counts were more elevated in the LMWH group than the control group, which is consistent with Huang et al. This shows that LMWH can elevate the lymphocyte count and contribute to an improvement of the disease. There are some causes for this. First, LMWH consists mainly of oligosaccharides, and it can be explained that short oligosaccharide chains, which are common in LMWH, may lead to the compression of cytokine storms; in addition, oligosaccharide chains, which are reproduced from nitrous acid depolymerization of LMWH, are able to bind to antithrombin-III (AT-III), and this indicates that the therapeutic effect for the hypersensitivity of LMWH is independent of the anticoagulant impact [15–21].

One large trial on sepsis demonstrated that LMWH decreased mortality rates. This suggests that LMWH regressed the inflammation by its nonanticoagulant effects. Camprubi-Rimblas et al. revealed that LMWH may treat acute respiratory distress syndrome (ARDS) by improving lung inflammation. In addition, Paulsson et al. showed that heparin might heal a lung infection by struggling with heparan sulfate, which can cause a cytokine storm in COVID-19 by preventing the pathogens that bind host cells. However, the RASTEN study revealed that there was no significance detected in the survival time in lung cancer patients; although this was a disappointing outcome for LMWH, the dose of the molecule in this study was prophylactic, and the stage of the participants was higher; therefore, these results are incongruous [22–24].

Researchers and medical personnel have found that age and comorbidity are possible risk factors for patients who are infected with COVID-19. Moreover, some studies have demonstrated that thorax CT scans and laboratory markers, such as complete blood count, liver enzyme markers, coagulation parameters, inflammatory markers, and the quantity of immune cells of COVID-19 patients, are connected with the severity of the illness [25–27].

In some studies on COVID-19, the D-dimer levels were increased substantially according to disease severity.

| Univariable | OR (95% CI) | P value |
|-------------|-------------|---------|
| Age         | 1.041 (1.018–1.057) | 0.315   |
| Sex         | 0.732 (0.457–1.104) | 0.217   |
| BMI (kg/m²) | 0.538 (0.319–0.936) | 0.472   |
| CT-SS       | 12.30 (10.50–14.25) | <0.001  |

| Laboratory findings |
|---------------------|
| WBC (k/uL)          | 2.485 (1.821–3.178) | <0.001 |
| Neutrophils (k/uL)  | 1.514 (1.137–1.749) | <0.001 |
| Lymphocyte (k/uL)   | 0.203 (0.015–0.322) | <0.001 |

| Antiinflammatory markers |
|--------------------------|
| CRP (mg/L)               | 0.362 (01.131–0.926) | <0.001 |
| D-DIMER (ng/mL)          | 0.657 (0.463–1.223)  | <0.001 |
| Fibrinogen               | 1.738 (1.176–2.549)  | <0.001 |

CT-SS: CT severity score, CRP: C reactive protein.

| Univariable | OR (95% CI) | P value |
|-------------|-------------|---------|
| Lymphocyte (k/uL) | -1.032 | 0.356 (0.089–0.674) | <0.001 |
| CRP (mg/L) | -0.465 | 0.628 (0.248–0.965) | <0.001 |
| D-DIMER (ng/mL) | -0.026 | 0.974 (0.476–1.594) | <0.001 |

Table 4. Univariate logistic regression analysis of risk factors with COVID-19 improvement.

Table 5. Multivariate logistic regression analysis of risk factors with COVID-19 improvement.
Tang et al. found that elevation of the D-dimer outcomes was correlated with mortality. Furthermore, Zhang et al. detected that elevated results of D-dimer affects hospital mortality, so this is a helpful parameter for following up the improvement of COVID-19 patients. Therefore, D-dimer was used as an evaluation index marker for the progression of the illness in this research. The mean outcomes of D-dimer were higher in the LMWH group than in the control group. This outcome is in line with the achievement of the LMWH performed group. The
determination of the differences demonstrated that LMWH had better efficacy for lowering D-dimer levels [11,28].

Novel studies have suggested that analyzing the CRP and lymphocyte counts revealed the efficacy of treatment of COVID-19. When we touched on the differences between the groups, significant differences were detected in the decreasing of the CRP results and the elevation in the lymphocyte counts of the LMWH group, as compared to the control group [29,30].

In the study analysis of CRP outcomes, Walters et al. indicated that LMWH reduces CRP outcomes, indicating its antiinflammatory effect. Furthermore, the ARMADA study revealed that inflammatory markers such as CRP were decreased in the heparin group. According to the control group, the CRP outcomes in the present study were lower in the LMWH group after the therapy period, which is in line with Walters et al. and the ARMADA study. This showed that LMWH can improve CRP levels and contribute to improvement of the disease [31,32].

Novel studies have also investigated some pathobiological perspectives, such as acquired thrombophilia in COVID-19, which were not evaluated previously and may enlighten future research. Patients with COVID-19 frequently have a higher risk for thrombotic situations. Therewithal, fibrin-based occlusions in microvessels have been found in the lung histopathology specimens examined in deceased COVID-19 patients [33–35].

Some synergistic mechanisms such as hypoxic vasoocclusion, activation of cells by viral transduction, and cytokine storms, which have been detected in COVID-19, may lead to micro- and/or macrothrombosis [36,37]. Furthermore, numerous studies have demonstrated that activated neutrophils conduce the spreading of thrombus, which affects vascular beds [38,39].

In accordance with these pathophysiological outcomes, some conventional gargling drugs suggested in the initial treatment of COVID-19 for leading oropharyngeal viral shedding, such as Ankaferd hemostat, contain Glycyrrhiza glabra, which contributes to antiinflammatory efficacy by way of a decline in the high mobility group box 1 protein [HMGB1] secretion [40].

Through the logistic univariate regression model, this study detected that WBC outcomes, the lymphocytes count, neutrophils, D-dimer, FIB, CRP, and PLT were

**Figure 3.** ROC curve for risk factors in patients infected with COVID-19. ROC = receiver operating characteristic.
independent risk factors for participants. Moreover, some studies have shown that most of the patients infected with COVID-19 displayed lymphocytopenia, elevated D-dimer levels, CRP, and, in some cases, elevated liver enzymes such as AST and ALT. Hematologic and biochemical outcomes were seriously elevated in patients who were followed up at an ICU, recommending that the severity of the disease may have a relationship with cytokine storms and hyper inflammation. In addition, the logistic multivariate analysis model demonstrated that D-dimer, CRP levels, and lymphocyte counts were the main risk factors for disease severity, which has a relationship with inflammation and hypercoagulation [41,42].

Although some scoring modules have more variables correlated with disease prognosis, no scoring system has been accepted as a rule. Gong et al. formulated a seven-parameter system that included complete blood count and biochemical markers for identification of severity [43]. Chen et al. also performed a system for predicting the prognosis of the disease, including comorbidities, antiinflammatory markers, and demographics [44]. The present study utilized the scoring system designed by Dong et al. for evaluating disease severity and assessing the treatment time by a simple formula, in comparison to other systems that are confusing and may lead to misunderstandings [45]. Although the present system only contains 3 variables, it has better efficacy for distinguishing participants whose progress may turn to severity and respond to treatment conveniently. CRP was used as a scoring parameter, instead of the erythrocyte sedimentation rate (ESR), for evaluating antiinflammatory efficacy more clearly [46]. In comparison to these studies, the present scoring system is a simple and rapid detecting module for patients whose prognosis may become worse.

In addition to the scoring system, this research assessed the TST-CT outcomes for evaluating the improvement of patients and used it to assist in observing the improvement in the lungs. TST-CT is a sensitive apparatus and is better than chest x-rays for investigating the pulmonary parenchyma. Therefore, this method has become a pioneer diagnostic, and it is a helpful method for early detection of COVID-19. The characteristic radiological outcome of COVID-19 is ground-glass opacities and/or consolidation asymmetrically located at peripheral lodges. The radiological manifestations are similar to those of SARS and MERS. The SARS and MERS diseases both frequently show single lesions unilaterally and asymmetrically in the lungs. The TST-CT scores and the screened lesions were improved at the end of the follow-up period, according to the initial time outcomes [47,48].

This study had some limitations. First, it was a retrospective study, and the patient population was small; however, the sample size was considered adequate to draw relevant conclusions. The present study showed that research groups have an inclusive population treated in our center. Second, none of the patients who were treated in the ICU joined the study; all the participants were discharged and had no complications or mortality detected. Finally, the influence of other novel therapies on these patients was not evaluated. Because the research period lasted a little over 1 week, it is possible that some nonpharmacological changes were introduced in the management of patients as medical institutes learned more about this disease over time.

5. Conclusion
In conclusion, this research suggests that LMWH therapy, added to conventional treatment, can contribute to clinical and laboratory improvement in COVID-19. Those improvements might be the result of the antiinflammatory effects of LMWH.

Acknowledgement/Disclaimers/Conflict of interest
The authors declare that they have no conflict of interest. The authors declare that they have no potential benefits in any form from a commercial party related directly or indirectly to the subject of this manuscript. They also declare that there was no funding source for conducting this study.

Informed consent
This research was approved by the Ministry of Health Committee (approval number: 2020/37) and conducted in accordance with the principles of the Declaration of Helsinki (2).

Ethical Approval
The University Hospital of Medicine faculty approved the study (COVID-19–2020, No. 2020/037). This study was performed in accordance with the Helsinki Declaration of 1964 and its subsequent amendments.

References
1. Perlman S. Another decade, another coronavirus. The New England Journal of Medicine 2020; 382: 760-762.doi: 10.1056/NEJMe2001126
2. World Health Organization (WHO). Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (2019-nCoV) Infection Is Suspected: Interim Guidance, WHO/2019-nCoV/clinical/2020.5; (2020).
3. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-CoV-2) outside of Wuhan, China: retrospective case series. British Medical Journal Version 2. BMJ 2020; 368: 606-613. doi: 10.1136/bmj.m606

4. Liu Y, Yang Y, Zhang C, Huang F, Wang F et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Science China Life 2020; 63 (3): 364-374. doi: 10.1007/s11427-020-1643-8

5. Chan MH, Wong VW, Wong CK, Chan PKK, Chu CM et al. Serum LD1 isoenzyme and blood lymphocyte subsets as prognostic indicators for severe acute respiratory syndrome. Journal of Internal Medicine 2004; 255 (4): 512-518. doi: 10.1111/j.1365-2796.2004.01323.x

6. Hou H, Zhang B, Huang H, Luo Y, Wu S et al. Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19. Clinical Experimental Immunology 2020; 201(1): 76-84. doi: 10.1111/cei.13450

7. Wang D, Hu B, Hu C, Zhu F, Li X et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus infected pneumonia in Wuhan, China. Journal of The American Medical Association 2020; 323 (11): 1061-1069. doi: 10.1001/jama.2020.1585

8. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Sergentanis TN et al. Hematological findings and complications of COVID-19. American Journal of Hematology. 2020; 95 (7): 834-847. doi: 10.1002/ajh.25829

9. Tang N, Bai H, Chen X, Gong J, Li D et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of Thrombosis and Haemostasis 2020; 18 (5): 1094-1099. doi: 10.1111/jth.14817

10. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis 2020; 18 (4): 844-847. doi: 10.1111/jth.14768

11. Chang YC, Yu CJ, Chang SC, Galvin JR, Liu HM et al. Pulmonary sequelae in convalescent patients after severe acute respiratory syndrome: evaluation within-section CT. Radiology 2005; 236 (3): 1067-1075. doi: 10.1148/rad.2363040958

12. Tichelaar YI, Kuin-Nelemans JCH, Meijeret K. Infections and inflammatory diseases as risk factors for venous thrombosis. A systematic review. Thrombosis and Haemostasis 2012; 107 (5): 827-837. doi: 10.1160/TH11-09-0611

13. Downing LJ, Strieter RM, Kadell AM, Wilke CA, Greenfield LJ et al. Low-dose low-molecular-weight heparin is anti-inflammatory during venous thrombosis. Journal of Vascular Surgery 1998; 28 (5): 848-854. doi: 10.1016/s0741-5214(98)70060-6

14. Ahmed T, Garrigo J, Danta I. Preventing broncho constriction in exercise-induced asthma within haled heparin. New England Journal of Medicine 1993; 329 (2): 90-95. doi: 10.1056/NEJM199307083290204

15. Li X, Wang L, Yan S, Yang F, Xiang L et al. Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China. International Journal of Infectious Disease 2020; 94: 128-132. doi: 10.1016/j.ijid.2020.03.053

16. Li L, Tian H, Yong W, Zheng W, Yuan L et al. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. Journal of Medical Virology 2020; 92 (6): 577-583. doi: 10.1002/jmv.25757

17. Huang C, Wang Y, Li X, Ren L, Zhao J et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223): 497-506. doi: 10.1016/S0140-6736(20)30183-5

18. Ahmed T, Smith G, Vlahov I, Abraham WM. Inhibition of allergic airway responses by heparin derived oligosaccharides: identification of a tetrasaccharide sequence. Respiratory Research 2012; 13 (1): 6. doi: 10.1186/1465-9921-13-6

19. Shastr MD, Stewart N, Eapen M, Peterson GM, Zaidi ST et al. Opposings of low molecular weight heparins on the release of inflammatory cytokines from peripheral blood mononuclear cells of asthmatics. PLoS One 2015; 10 (3): e0118798. doi: 10.1371/journal.pone.0118798

20. Shastr MD, Stewart N, Horne J, Peterson GM, Gueven N et al. In vitro suppression of IL-6 and IL-8 release from human pulmonary epithelial cells by non-anticoagulant fraction of enoxaparin. PLoS One 2015; 10 (5): e0126763. doi: 10.1371/journal.pone.0126763. eCollection 2015

21. Shastr MD, Stewart N, Horne J, Zaidi ST, Sohal S et al. Non-anticoagulant fractions of enoxaparin suppress inflammatory cytokine release from peripheral blood mononuclear cells of allergic asthmatic individuals. PLoS One 2015; 10 (6): e0128803. doi: 10.1371/journal.pone.0128803

22. Camprubi-Rimblas M, Guillamat-Prats R, Lebouvier T, Bringue J, Chimenti L et al. Role of heparin in pulmonary cell populations in an in vitro model of acute lung injury. Respiratory Research 2017 May 10; 18 (1): 89-95. doi: 10.1186/s12931-017-0572-3

23. Paulsson M, Riesbeck K. How bacteria hack the matrix and dodge the bullets of immunity. European Respiratory Review 2018; 27 (148): 180018. doi: 10.1183/16000617.0018-2018

24. Ek L, Gezelius E, Bergman B, Bendahl PO, Anderson H et al. Swedish lung cancer study group (SLUSG): randomized phase III trial of low-molecular weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial. Annals of Oncology 2018; 29 (2): 398-404. doi: 10.1093/annonc/mdx716

25. He JL, Luo L, Luo ZD, Lyu JX, Ng MY et al. Diagnostic performance between CT and initial real-time RT-PCR for clinically suspected 2019 corona virus disease (COVID-19) patients outside Wuhan, China. Respiratory Medicine 2020; 168: 105980. doi: 10.1016/j.rmed.2020.105980

26. Liu P, Tan XZ. 2019 Novel Coronavirus (2019-nCoV) pneumonia. Radiology 2020 Feb 04: 200257. doi: 10.1148/radiol.2020200257
27. Chung M, Bernheim A, Mei X, Zhang N, Huang M et al. CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology 2020. doi: 10.1148/radiol.2020200230

28. Zhang L, Yan Q, Fan H, Liu X, Liu Z et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. Journal of Thrombosis and Hemostasis: JTH. 2020; 18 (6): 1324-1329. doi: 10.1111/jth.14859

29. Mousavi S, Moradi M, Khorsheidahmad T, Motamedi M. Anti-inflammatory effects of heparin and its derivatives: a systematic review. Advances in Pharmacological Sciences 2015: 507151. doi: 10.1155/2015/507151

30. Oldgren J, Fellenius C, Boman K, Jansson JH, Nilsson TK et al. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). The American Journal of Cardiology 2003; 91 (8): 925-930. doi: 10.1016/s0002-9149(03)00105-x

31. Walters DL, Ray MJ, Wood P, Perrin EJ, Bett JHN et al. Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease. Internal Medicine 2005; 258 (5): 420-427. doi: 10.1111/j.1365-2796.2005.01562.x

32. Montalescot G, Bal-dit-Sollier C, Chibedi D, Collet JP, Soulat T et al. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). The American Journal of Cardiology 2003; 91 (8): 925-930. doi: 10.1016/s0002-9149(03)00105-x

33. Tian S, Weidong H, Li N, Huan L, Haibo X et al. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. Journal of Thoracic Oncology 2020; 15 (5): 700-704. doi: 10.1016/j.jtho.2020.02.010

34. Zhe X, Lei S, Yijin W, Jiyuan Z, Lei H et al. Neutrophil extracellular traps: villains and targets in arterial, venous, and cancer-associated thrombosis. Arteriosclerosis Thrombosis and Vascular Biology 2019; 39 (9): 1724-1738. doi: 10.1161/ATVBAHA.119.312463

35. Fox SE, Aibek A, Jack LH, Guang L, Brown JQ et al. Neutrophil extracellular traps. Journal of Experimental Medicine 2017, 2020 Jun 1; 217 (6): e20200652. doi: 10.1084/jem.20200652

36. Thalin C, Hisada Y, Lundstrom S, Mackman N, Wallen H. Neutrophil extracellular traps: villains and targets in arterial, venous, and cancer-associated thrombosis. Arteriosclerosis Thrombosis and Vascular Biology 2019; 39 (9): 1724-1738. doi: 10.1161/ATVBAHA.119.312463

37. Barnes BJ, Jose MA, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. Journal of Experimental Medicine 2021, 2020 Jun 1; 217 (6): e20200652. doi: 10.1084/jem.20200652

38. Kapoor S, Opneja A, Nayak L. The role of neutrophils in thrombosis. Thrombosis Research 2018; 170: 87-96. doi:10.1016/j.thromres.2018.08.005

39. Fang BE, Chong VCL, Stephrene Seok Wei C, GekHsiang L, Kian Guan Eric L et al. Hematologic parameters in patients with COVID-19 infection. American Journal of Hematology 2020; 95 (6): E131-E134. doi: 10.1002/ajh.25774

40. Guan WJ, Zheng-Yini, Hu Y, Liang WH, Chun-Quan O et al. Clinical characteristics of Coronavirus disease 2019 in China. The New England Journal of Medicine 2020; 382 (18): 1708-1720. doi: 10.1056/NEJMoa2002032

41. Dong Y, Zhou H, Li M, Zhang Z, Guo W et al. A novel simple scoring model for predicting severity of patients with SARS-CoV2 infection. Transboundary and Emerging Diseases 2020: 1-15. doi:10.1111/tbed.13651

42. Chen R,Liang W, Jiang M, Guan W, Zhan C et al. Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China. Chest. 2020; 158 (1): 97-105. doi: 10.1016/j.chest.2020.04.010

43. Guo PF, Li R, Xu C, Chai W, Li H et al. A clinical plot study to evaluate CD64 expression on blood monocytes as an indicator of periprosthetic joint infection. Journal of Bone and Joint Surgery American 2020; 102(17):e99. doi: 10.2106/JBJS.20.00057

44. Dong Y, Zhou H, Li M, Zhang Z, Guo W et al. A novel simple scoring model for predicting severity of patients with SARS-CoV2 infection. Transboundary and Emerging Diseases 2020: 1-15. doi:10.1111/tbed.13651

45. Qu PF, Li R, Xu C, Chai W, Li H et al. A clinical plot study to evaluate CD64 expression on blood monocytes as an indicator of periprosthetic joint infection. Journal of Bone and Joint Surgery American 2020; 102(17):e99. doi: 10.2106/JBJS.20.00057

46. Wu J, Wu X, Zeng W, Guo D, Fang Z et al. Chest CT findings in patients with corona virus disease 2019 and its relationship with clinical features. Investigative Radiology 2020; 55 (5): 257-261. doi: 10.1097/RLI.0000000000000670

47. YORMAZ et al. / Turk J Med Sci